This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.
Please go to www.ahrq.gov for current information.
Table 14. Tumor Characteristics Predictive of Response or Survival Among EGFR-TK Inhibitor Studiesd
| Characteristic |
Favorable Prognostic Factor |
No. of studies indicating an association with response |
References |
No. of studies indicating an association with survival |
References |
| Histologic type |
Adeno vs. non-adeno |
10/17 |
13,25,29,42,48,49,70 |
4/4 |
25,38,42,57 |
| |
BAC vs. non-BAC |
2/4 |
50,71 |
|
|
| |
Adeno/BAC vs. adeno, non-BAC vs. other |
2/2 |
53,56 |
1/1 |
56 |
| |
Papillary vs. non-papillary |
1/1 |
72 |
1/1 |
72 |
| Grade |
Well/moderately vs. poorly differentiated |
|
|
2/2 |
54,73 |
| Stromal invasion |
|
|
|
1/1 |
73 |
| Mucin production |
|
|
|
1/1 |
73 |
| Expression by IHC |
|
|
|
|
|
| EGFR |
Low vs. high |
4/12 |
25,31,50,52,65,72,74-79 |
3/4 |
25,50,73,74 |
| HER2/erbB2 |
2+/3+ vs. 0/1+ |
2/6 |
50,65,70,72,78,80 |
1/2 |
73,80 |
| p-EGFR |
- - |
0/4 |
52,65,72,76 |
0/1 |
81 |
| p-Akt status |
Positive vs. negative |
2/6 |
50-52,63,65,78 |
1/3 |
50,67,70 |
| p-Erk/p-MAPK |
2+/3+ vs. 0/1+ |
3/6 |
50-52,63,65,76 |
1/1 |
73 |
| p-STAT3 |
|
0/1 |
52 |
|
|
| P53 |
|
0/1 |
78 |
|
|
| Ki-67 |
|
1/1 |
65 |
2/2 |
65,73 |
| CYFRA 21-1 |
> 3.5 ng/ml
vs. < or = 3.5 ng/ml |
- - |
|
1/2 |
46,67 |
| EGFR mutation |
Mutation vs. wild type |
19/23 |
13,21,42,48-51,66,70,82-93 |
7/11 |
13,42,50,66,67,70,87,89,92,93 |
| KRAS mutation |
Mutation vs. wild type |
1/3 |
21,36,89 |
0/2 |
89,94 |
d Results of multivariable analysis reported in preference to results of univariable analyses when both were available.
Abbreviations: Adeno = adenocarcinoma; Adeno/BAC = adenocarcinoma with bronchoalveolar carcinoma features; BAC = bronchoalveolar carcinoma; EGFR = epidermal growth factor receptor; EGFR-TK = epidermal growth factor receptor tyrosine kinase; IHC = immuno histochemistry; No. = number
Return to Document
|
540 Gaither Road Rockville, MD 20850